90 related articles for article (PubMed ID: 22027395)
1. Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay.
Fischer SM; Buckley ST; Kirchmeyer W; Fricker G; Brandl M
Int J Pharm; 2012 Jan; 422(1-2):52-8. PubMed ID: 22027395
[TBL] [Abstract][Full Text] [Related]
2. Drug permeability across a phospholipid vesicle-based barrier 2. Characterization of barrier structure, storage stability and stability towards pH changes.
Flaten GE; Bunjes H; Luthman K; Brandl M
Eur J Pharm Sci; 2006 Jul; 28(4):336-43. PubMed ID: 16697561
[TBL] [Abstract][Full Text] [Related]
3. Drug permeability across a phospholipid vesicle based barrier: 3. Characterization of drug-membrane interactions and the effect of agitation on the barrier integrity and on the permeability.
Flaten GE; Skar M; Luthman K; Brandl M
Eur J Pharm Sci; 2007 Mar; 30(3-4):324-32. PubMed ID: 17204409
[TBL] [Abstract][Full Text] [Related]
4. Biomimetic PVPA in vitro model for estimation of the intestinal drug permeability using fasted and fed state simulated intestinal fluids.
Naderkhani E; Vasskog T; Flaten GE
Eur J Pharm Sci; 2015 Jun; 73():64-71. PubMed ID: 25840125
[TBL] [Abstract][Full Text] [Related]
5. In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants.
Fischer SM; Flaten GE; Hagesæther E; Fricker G; Brandl M
J Pharm Pharmacol; 2011 Aug; 63(8):1022-30. PubMed ID: 21718285
[TBL] [Abstract][Full Text] [Related]
6. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers.
Ingels F; Beck B; Oth M; Augustijns P
Int J Pharm; 2004 Apr; 274(1-2):221-32. PubMed ID: 15072798
[TBL] [Abstract][Full Text] [Related]
7. In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier.
Kanzer J; Tho I; Flaten GE; Mägerlein M; Hölig P; Fricker G; Brandl M
J Pharm Pharmacol; 2010 Nov; 62(11):1591-8. PubMed ID: 21039543
[TBL] [Abstract][Full Text] [Related]
8. Solid phospholipid nano-particles: investigations into formulation and dissolution properties of griseofulvin.
Brinkmann-Trettenes U; Bauer-Brandl A
Int J Pharm; 2014 Jun; 467(1-2):42-7. PubMed ID: 24614583
[TBL] [Abstract][Full Text] [Related]
9. Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion.
Flaten GE; Dhanikula AB; Luthman K; Brandl M
Eur J Pharm Sci; 2006 Jan; 27(1):80-90. PubMed ID: 16246536
[TBL] [Abstract][Full Text] [Related]
10. Mimicking regional and fasted/fed state conditions in the intestine with the mucus-PVPA in vitro model: The impact of pH and simulated intestinal fluids on drug permeability.
Falavigna M; Klitgaard M; Steene E; Flaten GE
Eur J Pharm Sci; 2019 Apr; 132():44-54. PubMed ID: 30822502
[TBL] [Abstract][Full Text] [Related]
11. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs.
Fossati L; Dechaume R; Hardillier E; Chevillon D; Prevost C; Bolze S; Maubon N
Int J Pharm; 2008 Aug; 360(1-2):148-55. PubMed ID: 18539418
[TBL] [Abstract][Full Text] [Related]
12. Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound.
Frank KJ; Westedt U; Rosenblatt KM; Hölig P; Rosenberg J; Mägerlein M; Brandl M; Fricker G
Eur J Pharm Sci; 2012 Aug; 47(1):16-20. PubMed ID: 22579958
[TBL] [Abstract][Full Text] [Related]
13. Drug permeability across a phospholipid vesicle-based barrier 4. The effect of tensides, co-solvents and pH changes on barrier integrity and on drug permeability.
Flaten GE; Luthman K; Vasskog T; Brandl M
Eur J Pharm Sci; 2008 Jul; 34(2-3):173-80. PubMed ID: 18499410
[TBL] [Abstract][Full Text] [Related]
14. A dynamic in vitro permeation study on solid mono- and diacyl-phospholipid dispersions of celecoxib.
Jacobsen AC; Elvang PA; Bauer-Brandl A; Brandl M
Eur J Pharm Sci; 2019 Jan; 127():199-207. PubMed ID: 30408522
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF.
Wuyts B; Riethorst D; Brouwers J; Tack J; Annaert P; Augustijns P
Eur J Pharm Sci; 2015 Jan; 67():126-135. PubMed ID: 25433246
[TBL] [Abstract][Full Text] [Related]
16. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
Wei H; Löbenberg R
Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
[TBL] [Abstract][Full Text] [Related]
17. Investigation of solubilising effects of bile salts on an active pharmaceutical ingredient with unusual pH dependent solubility by NMR spectroscopy.
Vogtherr M; Marx A; Mieden AC; Saal C
Eur J Pharm Biopharm; 2015 May; 92():32-41. PubMed ID: 25720817
[TBL] [Abstract][Full Text] [Related]
18. Development of a biomimetic phospholipid vesicle-based permeation assay for the estimation of intestinal drug permeability.
Naderkhani E; Isaksson J; Ryzhakov A; Flaten GE
J Pharm Sci; 2014 Jun; 103(6):1882-90. PubMed ID: 24665049
[TBL] [Abstract][Full Text] [Related]
19. Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids.
Clarysse S; Brouwers J; Tack J; Annaert P; Augustijns P
Eur J Pharm Sci; 2011 Jul; 43(4):260-9. PubMed ID: 21570465
[TBL] [Abstract][Full Text] [Related]
20. Characterization and evaluation of a modified PVPA barrier in comparison to Caco-2 cell monolayers for combined dissolution and permeation testing.
Gantzsch SP; Kann B; Ofer-Glaessgen M; Loos P; Berchtold H; Balbach S; Eichinger T; Lehr CM; Schaefer UF; Windbergs M
J Control Release; 2014 Feb; 175():79-86. PubMed ID: 24361370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
